e-mail from Haze Hanze e-mailed me in private and here's what he had to say. "I hope you don't mind me trying to talk down the price of IMM but I don't want to pay any more than I have to for the stock." He went on to say, "The bio-tech sector is obviously the segment of the market that is next to soar just as the tech market in general did until March of this year. Except in this case it will be sustained far into the future as the tidal wave of baby boomers roll through middle age and beyond and puts dramatic pressures on the health system. Disease remedies and health enhancements of all kinds will be in huge demand and will be well funded by the affluence of these baby boomers. This in turn will open tremendous opportunities for the pharmaceutical industry that supplies them and for the bio-tech companies that discover and develope them. The rewards for successfully developing and marketing such remedies will be truly astounding. Hanze added, "IMM's strategy of buying BCR with it's proven track record, it's location on the UBC campus, it's revenues, and most importantly it's own lab fascilities is an exciting and inciteful approach to incubating companies in the bio-tech arena. Already funded with over 6 million, the future looks bright and promising for IMM." Thanks for the message Hanze.